Angelo Ong-Veloso, MD
Internal Medicine · Lake Havasu City, AZNPI 1124020284
Payments from drug & device makers
Across 134 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$367
- Pfizer$269
- Johnson & Johnson$223
- Novo Nordisk$139
- Lilly USA, LLC$132
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$129
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,33499%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 21 | $367 |
| Pfizer | 17 | $269 |
| Johnson & Johnson | 14 | $223 |
| Novo Nordisk | 8 | $139 |
| Lilly USA, LLC | 7 | $132 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $129 |
| Bayer | 5 | $104 |
| Novartis | 5 | $91 |
| Merck | 6 | $91 |
| AbbVie(2 entities) | 6 | $82 |
| UCB, Inc. | 3 | $78 |
| E.r. Squibb & Sons, L.L.C. | 5 | $67 |
| Lucid Diagnostics Inc. | 3 | $50 |
| Sun Pharmaceutical Industries Inc. | 2 | $46 |
| Abbott | 1 | $43 |
| Sanofi Pasteur Inc. | 2 | $43 |
| GSK | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Exact Sciences | 2 | $29 |
| AstraZeneca | 2 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Philips North America LLC | 1 | $21 |
| Alvogen Inc | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Vertex | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Itamar Medical Inc | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $15 |
How this compares
$2,353 in reported general payments places this provider in the 85th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 337 | $152,295 |
| MounjaroTirzepatide | 90 | $115,631 |
| OzempicSemaglutide | 104 | $104,696 |
| XareltoRivaroxaban | 144 | $71,632 |
| OtezlaApremilast | 13 | $62,309 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $55,798 |
| TrulicityDulaglutide | 40 | $46,532 |
| FarxigaDapagliflozin Propanediol | 67 | $39,233 |
| JardianceEmpagliflozin | 70 | $38,372 |
| MyrbetriqMirabegron | 67 | $31,327 |
| JanuviaSitagliptin Phosphate | 41 | $28,664 |
| EntrestoSacubitril/Valsartan | 47 | $18,592 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 60 | $18,536 |
| LinzessLinaclotide | 24 | $18,204 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $13,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $132 | $162,163130 claims |
| PfizerEliquis | $269 | $152,295337 claims |
| Novo NordiskOzempic | $139 | $104,696104 claims |
| Johnson & JohnsonXarelto | $223 | $71,632144 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $41 | $68,71478 claims |
| AmgenOtezla | $367 | $62,30913 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere, Symbicort | $28 | $62,102144 claims |
| Boehringer IngelheimJardiance, Tradjenta | $19 | $47,61987 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $31,32767 claims |
| MerckJanuvia | $91 | $28,66441 claims |
| NovartisEntresto | $91 | $18,59247 claims |
| AbbVieLinzess | $82 | $18,20424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Lake Havasu City
- Yessica SachdevaMesa$13.7M
- Louise TaberPhoenix$8.5M
- Janelle WeyerChandler$5.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
- Justin MoserScottsdale$3.9M
- Franz RischardTucson$3.7M
- Randall SeveranceChandler$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.